Novel agent induced high response rate in high-risk CLL, SLL Healio A phase 2 monotherapy study in patients with relapsed del(17p) CLL is under way, as have combination studies with either rituximab (Rituxan, Genentech/Biogen Idec) or obinutuzumab (Gazyva, Genentech) in patients with relapsed CLL, according to the ... |
